Supply of Laboratory Equipment (Part LXXXIII) for SES of the Republic of Uzbekistan.

New clarification added: Q.7:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B11)Kinetic reaction curves constitute internal analytical data used for result calculation and do not require direct access through the user interface, as they are not typically relevant for routine user interpretation or clinical decision-making. Requiring on-screen graphical display of kinetic reaction curves introduces a user-interface–specific feature rather than a functional analytical requirement and may unnecessarily limit competition.To support functional equivalence while maintaining analytical integrity, it may be sufficient that kinetic reaction data be stored within the device memory and be retrievable or made available by the manufacturer upon user request, rather than mandating real-time graphical display on the LCD screen.In this context, and in order to ensure a fair and competitive environment for all bidders, please clarify whether the requirement may be revised as follows:Kinetic analysis with reaction curve display on the LCD screen, or system compatibility with an equivalent measurement method.A.7:On-screen graphical display of kinetic reaction curves is considered a valuable functional feature for biochemistry analyzers, as it supports enhanced data interpretation, improved quality control, and more effective troubleshooting. For these reasons, the technical specifications remain unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.6:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B13)In veterinary laboratories and clinical settings, biochemistry analyzers are primarily used to support immediate diagnostic decision-making. Long-term data storage is typically managed through external systems, such as clinic management software or electronic archiving solutions, following the export of analytical results. As such, internal memory capacity does not represent a critical performance parameter when the analyzer supports reliable data export in standard formats, including CSV and PDF.An internal memory capacity of approximately 200 patient records is generally sufficient for routine veterinary workflows, provided that the system enables dependable result export, report generation, and data traceability. Once data have been transferred to an external computer or workstation, the system may be configured to store results for approximately 200 patients, after which internal memory is typically cleared. Under these conditions, high-capacity internal storage is not operationally necessary.In this context, and in order to ensure a fair and competitive environment for all bidders, please clarify whether the requirement may be revised as follows:Memory for at least 5,000 results or at least 200 patients, or equivalent; ability to export data in CSV and PDF formats; and capability to print labels and reports via a workstation.A.6:The technical specifications remain unchanged. Proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.5:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B12)Dry chemistry analyzers are designed and validated to operate with specific analytical methodologies and reagent chemistries in order to ensure accuracy, precision, traceability, and patient safety. Compatibility with any methodology or reagent cannot be technically guaranteed, as different reagents require distinct reaction principles, calibration models, incubation conditions, and quality control parameters.From a regulatory and quality management perspective, analyzer performance can only be assured when validated and manufacturer-approved methodologies and reagents are used. Requiring unrestricted compatibility with any methodology or reagent may adversely affect analytical reliability and is inconsistent with good laboratory practice and established quality management standards.Furthermore, in cases where supply chain continuity and reagent availability are ensured and do not present a risk, it may be appropriate to permit the use of systems that are not limited to open-system configurations.In this context, and in order to ensure a fair and competitive environment for all bidders, please clarify whether the requirement may be revised as follows:Open system compatible with any methodologies and reagents, or equivalent closed dry chemistry system.A.5:The request to amend the analytical methodology from wet chemistry to dry chemistry does not align with the client’s specific operational needs. The selected wet chemistry methodology provides higher analytical accuracy, greater throughput, and a lower cost per test. In addition, open-system analyzers offer enhanced flexibility and cost control by enabling the use of reagents from multiple third-party suppliers. For these reasons, the technical specifications remain unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.4:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B10)The specified requirement refers to wet chemistry analyzers that operate using liquid reagents and physical measuring cells.Dry chemistry technology does not utilize cuvettes, tubes, or flow-through measuring cells. Instead, analytical measurements are performed on reagent slides based on a predefined linear calibration model (y = ax + b), delivering equivalent analytical performance. Despite the different measurement principle, such systems require low sample volumes and provide accurate, reproducible, and clinically equivalent results suitable for routine veterinary diagnostic applications.In this context, and in order to ensure a fair and competitive environment for all bidders, please clarify whether the requirement may be revised as follows:Measuring cell for cuvettes ≤ 1 cm, tubes ≤ 12 × 75 mm, or flow-through (minimum volume 250 µL), or equivalent dry chemistry method.A.4:The request to amend the analytical methodology from wet chemistry to dry chemistry does not align with the client’s specific operational needs. The selected wet chemistry methodology offers higher analytical accuracy, greater throughput, and a lower cost per test, which are essential for the intended application. Accordingly, the technical specifications remain unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.3:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B9)The specified optical density (OD) ranges are applicable to wet chemistry analyzers that operate using liquid reagents and conventional absorbance measurements performed in cuvettes.Dry chemistry systems, which are widely used in veterinary diagnostics, employ reflectance-based optical measurement on multilayer reagent slides rather than conventional cuvette-based absorbance measurement. Due to these fundamental differences in measurement principles, optical density range specifications expressed for cuvette-based systems cannot be directly applied to or compared with dry chemistry analyzers.Notwithstanding this difference, dry chemistry analyzers are capable of delivering accurate, linear, and reproducible analytical results, with proven clinical performance and broad acceptance in routine veterinary diagnostic practice.In this context, and in order to ensure a fair and competitive environment for all bidders, please clarify whether the requirement may be revised as follows:Optical density range:For tubes and 1 cm cuvettes: A ≥ −0.5 to ≤ 3.5;For flow-through cuvette: A ≥ −0.5 to ≤ 2.5;or equivalent dry chemistry measurement method.A.3:The request to amend the analytical methodology from wet chemistry to dry chemistry does not align with the client’s specific operational needs. The selected wet chemistry methodology provides higher analytical accuracy, greater throughput, and a lower cost per test, which are key considerations for the intended use. Accordingly, the technical specifications remain unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.2:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N B6)In veterinary diagnostics, serum iron is not generally considered a first-line or routine screening parameter and is typically requested only in selected clinical cases, such as the detailed investigation of specific types of anemia.For clinically meaningful interpretation, iron measurement requires complementary parameters, including Total Iron Binding Capacity (TIBC), ferritin, and transferrin saturation. As these complementary parameters are not included in the specified analytical panel, the standalone clinical utility of iron measurement is limited.In this context, please clarify whether iron (Fe) may be excluded from the mandatory panel requirements, or alternatively be offered as an optional, on-demand parameter.Further, in order to ensure a fair and competitive environment for all bidders, please clarify whether the mandatory analytical panel may be defined as follows:Measurement of at least the following parameters:ISE (K⁺, Na⁺, Cl⁻);General chemistry (amylase, albumin, creatinine, total protein, calcium, glucose, LDH, lipase, magnesium, phosphorus, CK, urea, uric acid);Lipids (cholesterol, HDL, triglycerides, LDL);Liver panel (ALP, ALT, ammonia, AST, bile acids, cholinesterase, GGT, bilirubin).A.2:The client’s specified requirements for the listed analytical parameters fully correspond to the intended clinical and research needs. Accordingly, the technical specifications remain unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.

New clarification added: Q.1:Clarification Request for Lot No. 2 – Biochemistry Analyzer (S/N A-1)Routine veterinary biochemistry testing is typically performed using serum or plasma samples, as the presence of cellular components in whole blood may interfere with photometric measurements and adversely affect analytical accuracy.While whole blood measurement technology is available in certain dry chemistry systems, its use does not provide a substantial clinical benefit for routine laboratory workflows. Instead, it may lead to increased system complexity and higher operational costs. Consequently, specifying analyzer models that deliver equivalent analytical performance through measurements conducted in serum or plasma would be sufficient to meet the intended performance objectives of the equipment.In this context, please clarify whether the technical specification may be amended as follows:“Automatic benchtop veterinary biochemistry analyzer for quantitative determination of biochemical parameters in serum, plasma, or whole blood of animals of various species (dogs, cats, horses, cattle, pigs, poultry, etc.)."A.1:The request to amend the specified sample type does not align with the client’s defined requirements. The requirement for whole blood analysis is based on the objective of minimizing sample preparation steps. Whole blood samples can be analyzed directly, which reduces processing time and limits the risk of pre-analytical errors associated with additional sample handling. By contrast, serum samples require clotting followed by centrifugation, while plasma samples require the addition of an anticoagulant prior to centrifugation.For these reasons, the technical specification regarding sample type remains unchanged.However, it is noted that proposed equipment presenting minor deviations from the stated requirements may be considered technically acceptable, subject to technical evaluation and confirmation and approval by the end user/client.